Skip to main content
Frontiers in Oncology logoLink to Frontiers in Oncology
. 2024 Feb 23;14:1278237. doi: 10.3389/fonc.2024.1278237

Frozen inactivated autograft replantation for bone and soft tissue sarcomas

Zhichao Tian 1, Shuping Dong 1, Yang Yang 2, Guoxin Qu 1, Guancong Liu 1, Xu Liu 1, Yue Ma 3, Xin Wang 1, Weitao Yao 1,*
PMCID: PMC10923239  PMID: 38463233

Abstract

Background

The frozen inactivation of autologous tumor bones using liquid nitrogen is an important surgical method for limb salvage in patients with sarcoma. At present, there are few research reports related to frozen inactivated autograft replantation.

Methods

In this study, we retrospectively collected the clinical data of patients with bone and soft tissue sarcoma treated with liquid nitrogen-frozen inactivated tumor bone replantation, and analyzed the safety and efficacy of this surgical method. The healing status of the frozen inactivated autografts was evaluated using the International Society of Limb Salvage (ISOLS) scoring system. Functional status of patients was assessed using the Musculoskeletal Tumor Society (MSTS) scale.

Results

This study included 43 patients. The average length of the bone defect after tumor resection is 16.9 cm (range 6.3–35.3 cm). Patients with autograft not including the knee joint surface had significantly better healing outcomes (ISOLS scores) (80.6% ± 15% vs 28.2% ± 4.9%, P<0.001) and limb function (MSTS score) (87% ± 11.6% vs 27.2% ± 4.4%, P<0.001) than patients with autografts including the knee joint surface. The healing time of the end of inactivated autografts near the metaphyseal was significantly shorter than that of the end far away from the metaphyseal (9.8 ± 6.3 months vs 14.9 ± 6.3 months, P=0.0149). One patient had local recurrence, one had an autograft infection, five (all of whom had an autograft including the knee joint surface) had joint deformities, and seven had bone non-union.

Conclusion

Frozen inactivated autologous tumor bone replantation is safe and results in good bone healing. But this method is not suitable for patients with autograft involving the knee joint surface.

Keywords: frozen inactivated, liquid nitrogen, autograft, replantation, osteosarcoma, sarcoma

1. Introduction

Although the incidence of osteogenic sarcoma or malignant tumors of the limbs that invade the bone is low, there are still tens of thousands of newly diagnosed cases worldwide every year (1). Historically, the treatment of bone-derived malignant tumors in the limbs has relied on simple amputation surgery. With the development of surgical techniques and the assistance of neo/adjuvant chemotherapy, the limb salvage rate of bone-derived malignant tumors can reach > 80% (2). Limb salvage surgery for bone-derived malignant tumors usually requires substitutes to repair bone voids following tumor resection and restore limb function. The currently available substitutes include artificial prostheses, autologous bone grafts, allogeneic bone grafts, and inactivated replantation of tumor bone (3, 4).

Inactivation and replantation of tumor bone refer to the removal of an entire block of bone eroded by a tumor (usually malignant or invasive), using various physical or chemical methods to inactivate it in vitro and then implanting it in situ (4). Compared to other limb salvage surgery methods, tumor bone inactivation and replantation have unique application values, including good matching of in situ replantation, no rejection reaction, and low cost (5). Therefore, this surgical method will be indispensable in the foreseeable future.

Tumor bone inactivation methods include pasteurization, microwave, ethanol, in vitro irradiation, and freezing (68). The use of liquid nitrogen to freeze and inactivate tumor bone has a clinical application history of over 20 years (9). This method involves immersing tumor bones in liquid nitrogen and using ultra-low temperatures of -196°C to destroy tumor cells. Freezing causes tumor cells to lose their activity by inducing ice crystal formation and cell dehydration. Only one cycle of -196°C for 20 minutes is sufficient to kill all tumor cells (10, 11). At present, there are not many research reports related to frozen inactivated autograft replantation. At a center for the diagnosis and treatment of bone and soft tissue sarcoma in a province with a population of nearly 100 million, we used frozen inactivated autograft replantation to treat bone-derived malignant tumors in our clinical work. In this study, we retrospectively collected the clinical data of these patients and reported the treatment efficacy and complications of this surgical method to provide a reference for relevant research and clinical treatment.

2. Methods

2.1. Patients and eligibility criteria

We retrospectively collected the clinical data of patients who met the inclusion criteria and received treatment at the investigator’s hospital between January 2016 and May 2022. The inclusion criteria were as follows: 1) pathological confirmation of bone and soft tissue sarcoma, 2) received frozen inactivated tumor bone replantation and reconstruction surgery, and 3) complete follow-up data.

This study was reviewed and approved by the hospital’s Medical Ethics Committee, and all treatments and research contents followed the principles of medical ethics.

2.2. Treatment protocol

All pathological diagnoses were confirmed by biopsy. Except for the patients with chondrosarcoma, all patients received preoperative and postoperative chemotherapy.

The resection length was determined based on preoperative magnetic resonance imaging. The tumor and surrounding normal tissue were removed as a whole, with a minimum edge of 2 cm. The epiphyseal plate was sacrificed if necessary. Any attached soft tissues or gross tumors were removed from the excised bone, and the bone canals were scraped. The tumor bone was frozen and inactivated using liquid nitrogen. In simple terms, after the extracted tumor bone was rinsed with normal saline, the bone was soaked in liquid nitrogen for 30–40 minutes and then thawed at room temperature (24–26°C) for 15–30 minutes. Frozen inactivated autogenous bone was implanted in situ into the bone defect and fixed with a locking plate. In some cases, intercalary grafts of autogenous fibula without a blood supply were used to enhance the strength of the inactivated bone.

Patients were encouraged to immediately begin a moderate range of exercises (whichever is painless) postoperatively. Partial weight-bearing was allowed one month after surgery. Only when a strong bone bonding is achieved is full weight-bearing allowed. Radiological evidence of bone connection at the osteotomy site includes blurred osteotomy lines or sufficiently bridging callus at the host-graft junction.

2.3. Collection and evaluation of clinical data

The baseline characteristics of all patients enrolled in this study were reviewed. Bone healing was evaluated using radiography every 3 months until the autograft healed. Follow-up was performed every 3 months in the first year and then every 6 months to check for recurrence and metastasis. We collected data on bone healing, limb function, and complications in these patients after undergoing frozen inactivated autograft replantation, as well as the relationship between their clinical characteristics, bone healing, and limb function.

In this study, the healing status of frozen inactivated autografts was evaluated using the International Society of Limb Salvage (ISOLS) scoring system, which is based on the scores for different parameters (fusion, resorption, fracture, graft shortening, fixation, subluxation, joint narrowing, and subchondral Bone) (12). A score of 100% indicated complete healing of the autograft, whereas a score of 0% indicated complete failure of autograft healing. We defined bone non-union as a condition in which one or both ends of the autograft had not yet fused 12 months after surgery until the fracture or follow-up deadline. Functional status was assessed using the Musculoskeletal Tumor Society (MSTS) scale, which is based on six parameters (pain, functional activity, emotional acceptance, use of external support, walking ability, and gait) (13). A score of 100% indicated a complete recovery of limb function, whereas a score of 0% indicated a complete loss of limb function.

2.4. Statistical analysis

Statistical analyses were performed using the SPSS software (version 21.0; IBM, Armonk, NY, USA). Quantitative variables were presented as numerical values (percentages), medians (ranges), or medians (interquartile range). A t-test was used to compare the differences in quantitative variables between the groups. All statistical analyses were two-sided, and a P value <0.05 was considered statistically significant. The follow-up data for this study were obtained as of May 31, 2023.

3. Results

The study included 43 patients who met the inclusion criteria ( Tables 1 , 2 ). Among them, there were 27 males and 16 females, with an average age of 22.6 (range 9–65) years. There were 30 patients with osteosarcoma, seven with Ewing’s sarcoma, three with chondrosarcoma, one with malignant peripheral nerve sheath tumor, one with round cell sarcoma, and one with myxofibrosarcoma. Most patients had lesions in the femur, followed by the tibia, humerus, radius, and ilium.

Table 1.

Clinical characteristics of patients who underwent frozen autograft reconstruction.

Patient No. Gender Age
(year)
Histology Primary site Length of autograft (cm) Contained articular surfaces Survival ISOLS score Bone healing time
(months)
Complications MSTS score
1 Male 20 Round cell sarcoma Tibia 20.7 No Yes 92% F site: 12 100%
2 Female 13 Osteosarcoma Tibia 12.5 No No 33% Not healed Infection 47%
3 Male 28 Ewing sarcoma Tibia 14.5 No No 71% Not healed 73%
4 Female 17 Ewing sarcoma Humerus 6.6 No Yes 79% C site: 13
F site: Not healed
Bone non-union 67%
5 Female 40 Osteosarcoma Tibia 13 No Yes 96% C site: 12
F site: 21
100%
6 Male 9 Osteosarcoma Femur 20 Yes No 25% F site: 8 Joint deformity 27%
7 Female 9 Ewing sarcoma Femur 13.5 No Yes 88% F site: 12 83%
8 Female 27 Osteosarcoma Humerus 16 Yes No 52% Not healed Recurrence 77%
9 Female 13 Osteosarcoma Tibia 24.2 Yes Yes 33% F site: 14 Joint deformity 33%
10 Male 21 Osteosarcoma Humerus 15 Yes No 83% Not healed 63%
11 Male 17 Osteosarcoma Tibia 19.2 No Yes 79% C site: 8
F site: 27
Bone non-union 70%
12 Male 15 Osteosarcoma Tibia 13.1 No Yes 96% F site: 8 97%
13 Male 48 Malignant peripheral nerve sheath tumor Tibia 15 No Yes 92% F site: 10 93%
14 Male 18 Osteosarcoma Radius 13.8 No Yes 96% C site: 15
F site: 15
97%
15 Male 17 Osteosarcoma Tibia 26.4 No Yes 88% F site:12 90%
16 Female 15 Ewing sarcoma Femur 18 No Yes 63% C site: 6
F site: not healed
Bone non-union 93%
17 Female 13 Osteosarcoma Femur 20.5 Yes No 33% F site: 9 Joint deformity 23%
18 Female 14 Osteosarcoma Femur 22.5 No Yes 83% F site: 15 93%
19 Male 22 Osteosarcoma Tibia 13.5 Yes Yes 28% C site: 7
F site: 27
Joint deformity 30%
20 Male 11 Osteosarcoma Tibia 19 No No 71% Not healed 87%
21 Male 15 Osteosarcoma Femur 12.5 No No 75% Not healed 83%
22 Male 65 Chondrosarcoma Ilium 9 No Yes 92% C site: 9
F site: 9
90%
23 Female 63 Myxofibrosarcoma Tibia 8 No No 79% Not healed 90%
24 Female 65 Chondrosarcoma Femur 25.9 No Yes 96% C site: 9
F site: 18
93%
25 Male 16 Ewing sarcoma Femur 18.4 No Yes 71% C site: 10
F site: Not healed
Bone non-union 87%
26 Male 12 Osteosarcoma Femur 16 No No 92% C site: 7
F site: 12
97%
27 Male 18 Osteosarcoma Humerus 19 Yes No 67% Not healed 70%
28 Male 17 Ewing sarcoma Femur 17 No No 88% C site: 8
F site: 21
93%
29 Female 10 Osteosarcoma Tibia 18.2 No Yes 96% C site: 7
F site: 13
100%
30 Female 11 Osteosarcoma Femur 11.8 No Yes 75% C site: 8
F site: not healed
87%
31 Male 14 Osteosarcoma Femur 18.6 No Yes 92% C site: 9
F site: 16
97%
32 Male 17 Osteosarcoma Femur 19 No Yes 63% C site: 6
F site: 17
90%
33 Male 32 Osteosarcoma Humerus 22.4 Yes Yes 58% Not healed Bone non-union 80%
34 Male 21 Osteosarcoma Femur 20.3 No Yes 67% C site: 34
F site: not healed
83%
35 Male 12 Osteosarcoma Femur 10 No No 96% C site: 8
F site: 8
90%
36 Male 27 Osteosarcoma Femur 17.5 No Yes 75% Not healed 90%
37 Female 53 Chondrosarcoma Femur 20.1 No Yes 79% C site: 9
F site: not healed
Bone non-union 87%
38 Male 10 Osteosarcoma Femur 23.5 Yes No 22% Not healed Bone non-union, Joint deformity 23%
39 Male 48 Osteosarcoma Tibia 19.5 Yes No 63% Not healed 90%
40 Female 14 Ewing sarcoma Ilium 8 No Yes 96% C site: 11
F site: 11
93%
41 Female 12 Osteosarcoma Femur 13 No Yes 88% C site: 7
F site: 30
97%
42 Male 17 Osteosarcoma Femur 35.3 No No 92% C site: 7
F site: 7
90%
43 Male 15 Osteosarcoma Radius 6.7 No Yes 100% C site: 15
F site: 15
100%

ISOLS, International Society of Limb Salvage; MSTS, Musculoskeletal Tumor Society; C site, osteotomy site closer to the epiphysis; F site, osteotomy site far from the epiphysis.

Table 2.

Pooled clinical characteristics of patients who underwent frozen autograft reconstruction.

Clinical characteristics Number of patients or value P
Gender
male 27 (63%)
female 16 (37%)
Age (year) 22.6 ± 15.6
Histology
osteosarcoma 30 (70%)
Ewing sarcoma 7 (16%)
chondrosarcoma 3 (7%)
others 3 (7%)
Primary site
femur 20 (46%)
tibia 14 (32%)
humerus 5 (12%)
radius 2 (5%)
ilium 2 (5%)
Length of autograft (cm) 16.9 ± 5.8
Whether the autograft contained articular surface of the knee joint
yes 5 (12%)
no 38 (88%)
Fixation with plate 43 (100%)
Average follow-up time (months) 31 (range 10–61)
Survival
yes 27 (63%)
no 16 (37%)
ISOLS score (%) <0.001
patients with the autograft containing the knee joint surface 28.2% ± 4.9%
patients with the autograft not containing the knee joint surface 80.6% ± 15%
Bone healing time (months) 0.0149
C site 9.8 ± 6.3
F site 14.9 ± 6.3
The site of Bone non-union
C site 0 (0%)
F site 7 (100%)
Complications
bone non-union 7
joint deformity 5
infection 1
recurrence 1
MSTS score (%) <0.001
patients with the autograft containing the knee joint surface 27.2% ± 4.4%
patients with the autograft not containing the knee joint surface 87% ± 11.6%

Data are presented as percentages (number events/total). ISOLS, International Society of Limb Salvage; C site, osteotomy site closer to the epiphysis; F site, osteotomy site far from the epiphysis; MSTS, Musculoskeletal Tumor Society.

The average follow-up duration was 31 months (10–61 months). Before the data deadline of this study, 27 (63%) patients were still alive, and 16 (37%) died of sarcoma metastasis. The average length of the bone defect after tumor resection is 16.9 cm (range 6.3–35.3 cm). The inactivated autograft of five patients included the articular surface of the knee joint. All patients underwent steel plate internal fixation. Patients who did not include the knee joint had significantly better healing outcomes (ISOLS scores) (80.6% ± 15% vs 28.2% ± 4.9%, P<0.001) and limb function (MSTS score) (87% ± 11.6% vs 27.2% ± 4.4%, P<0.001) than those who included the knee joint. The healing time of the end of inactivated autografts near the metaphyseal was significantly shorter than that of the end far away from the metaphyseal (9.8 ± 6.3 months vs 14.9 ± 6.3 months, P=0.0149) ( Figure 1 ).

Figure 1.

Figure 1

The healing process of frozen inactivated autologous tumor bone in a 15-year old female (case 37) with Ewing sarcoma involving the diaphysis of the left femur. (A) preoperative X-ray. (B) postoperative X-ray. (C) X-ray at 18 months postoperation. (D) X-ray at 20 months postoperation (At this point, the plate breaks). (E) X-ray at 11 months after last operation.

In terms of complications, one patient had local recurrence, one patient had infection of the autograft, five patients (all of which included the joint surface of the knee) had joint deformities ( Figure 2 ), and seven patients had bone non-union ( Figure 1 ).

Figure 2.

Figure 2

X-ray of patients with joint deformity. All five patients (case 6, 9, 17, 19, and 38, respectively) with inactivated bone containing the knee joint surface experienced this complication.

4. Discussion

In this study, we retrospectively collected the clinical data of patients with bone and soft tissue sarcomas treated with liquid nitrogen-frozen inactivated tumor bone replantation and analyzed the safety and efficacy of this surgical method. Among the 43 patients included, only one had local recurrence, and one had an autograft infection. Seven patients experienced bone non-unions. Most of the patients achieved bone healing. Bone healing and limb function of patients with autografts not including the knee joint surface were significantly better than those of patients with autografts including the knee joint surface.

The greatest risk of inactivated autologous tumor bone replantation is tumor recurrence due to incomplete inactivation. Historically, the methods used for inactivation include boiling, pasteurization, alcohol, radiation, and liquid nitrogen freezing used in this study (68). Among these methods, alcohol inactivation has the highest reported recurrence rate. This is related to the inability of alcohol to penetrate deep into the bone tissue (14). The recurrence rate in this study was relatively low, similar to that in other studies using liquid nitrogen inactivation (9, 15, 16), and similar to the recurrence rates for inactivation by boiling, pasteurization, and radiation (68). This demonstrates the safety of liquid nitrogen inactivation. However, there is still no standard for the duration of liquid nitrogen immersion. Our initial surgical plan used soaking for 40 min based on other studies. Subsequent patients were shortened to 30 min. The shortest reported soaking time was 20 min (11, 17). Currently, the shortest safe soaking time remains unknown.

Another major surgical risk associated with inactivation with liquid nitrogen is infection. Some studies have recommended the use of ultraviolet radiation for liquid nitrogen sterilization (16, 18). In this study, we used ordinary liquid nitrogen tank tubes to store liquid nitrogen and specialized containers for high-temperature disinfection to soak the tumor bone in liquid nitrogen. The infection rate in this study was low, suggesting that no additional ultraviolet irradiation was required to sterilize liquid nitrogen.

Difficulty in bone healing is a common problem in inactivated autologous bone replantation (3, 19). Difficulties in bone healing can lead to a series of complications, including non-union, fractures, internal fixation fractures, and long-term bone resorption (16, 19). Many researchers believe that freezing can completely preserve various osteogenic proteins in tumor bone segments. Therefore, similar to radiation inactivation, it is more conducive to bone healing than high-temperature inactivation (7, 16, 20). However, healing of frozen inactivated autografts remains difficult. In this study, we found that the sites with bone non-union were all at the ends of the inactivated autografts far from the metaphyseal region. The ends near the metaphysis healed smoothly ( Figure 1 ). This indicates that blood supply around the autograft is very important. Interestingly, inactivated autografts located in the middle of the radius healed smoothly. We speculate that this may be related to moderate pressure on the radius. Two patients (cases 16 and 37) with difficulty in bone healing in the middle of the femur underwent local autologous iliac cancellous bone grafting surgery, and the autograft healed within approximately one year. This indicates that autologous iliac cancellous bone-grafting surgery at the non-union site of inactivated autograft can effectively promote healing. Another noteworthy issue is the effect of age on the healing of inactivated bones. Currently, a small number of studies have focused on this issue, but due to the small sample size, it is not possible to draw definitive conclusions (21, 22). In this study, age did not seem to be a relevant factor for inactivated bone healing. However, due to the limited sample size, we are unable to draw a definitive conclusion here. These findings warrant further in-depth research.

Limb function recovery is an important indicator of the efficacy of inactivated autograft replantation surgery. Inactivated bone has optimal osteogenesis, osteoinduction, osteoconduction, and histocompatibility properties, along with the lower the risk of immunological rejection (3). Prosthetic replacement is an option to provide immediate stability and early weightbearing capability, but the risk of complications, such as loosening, infection, implant breakage and fracture of the adjacent bone may be higher than those for biological reconstructions (9). Therefore, in many cases, inactivated bone replantation can achieve better limb function than prosthesis replacement. This study further confirms this judgment. In this study, the limb function of patients with autograft that did not include the knee joint surface was better than that of patients who have undergone prosthesis replacement surgery (2325). However, the limb function of patients with autograft that included the knee joint surface was significantly poorer than that of patients with autograft that did not include the knee joint surface. All patients with autograft including the surface of the knee joint experienced severe joint dysfunction ( Figure 2 ). Other studies have identified this problem (26, 27). This indicates that inactivated autograft replantation is unsuitable for the treatment of malignant bone tumors involving the knee joint surface. The surgical method of inactivated autograft replantation combined with artificial joints can be used to improve the limb function of these patients (27, 28).

This study had some limitations, including its retrospective nature, small sample size, and lack of a control group. Additionally, this study included a heterogeneous sample with different diagnoses and tumor locations. All these factors make it difficult to analyze the differences in outcomes and complications. More patients and additional studies involving a control group are required to standardize this technique.

In conclusion, Liquid nitrogen-frozen inactivated autologous tumor bone replantation is safe and results in good bone healing. The bone healing and limb function of patients with frozen inactivated autografts that did not include the knee joint surface were significantly better than those of patients with autografts that included the knee joint surface.

Data availability statement

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.

Ethics statement

The studies involving humans were approved by Medical Ethics Committee of Henan Cancer Hospital. The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation in this study was provided by the participants’ legal guardians/next of kin. Written informed consent was obtained from the individual(s), and minor(s)’ legal guardian/next of kin, for the publication of any potentially identifiable images or data included in this article.

Author contributions

ZT: Conceptualization, Data curation, Investigation, Methodology, Validation, Writing – original draft. SD: Data curation, Investigation, Writing – original draft. YY: Data curation, Formal analysis, Methodology, Software, Writing – original draft. GQ: Data curation, Investigation, Writing – original draft. GL: Data curation, Investigation, Writing – original draft. XL: Investigation, Writing – original draft. YM: Investigation, Writing – original draft. XW: Conceptualization, Investigation, Resources, Writing – review & editing. WY: Conceptualization, Resources, Writing – review & editing.

Funding Statement

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

  • 1. Blay JY, Palmerini E, Bollard J, Aguiar S, Angel M, Araya B, et al. SELNET clinical practice guidelines for bone sarcoma. Crit Rev Oncol hemat. (2022) 174:103685. doi:  10.1016/j.critrevonc.2022.103685 [DOI] [PubMed] [Google Scholar]
  • 2. Bläsius F, Delbrück H, Hildebrand F, Hofmann UK. Surgical treatment of bone sarcoma. Cancers (Basel). (2022) 14:null. doi: 10.3390/cancers14112694 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Migliorini F, La Padula G, Torsiello E, Spiezia F, Oliva F, Maffulli N. Strategies for large bone defect reconstruction after trauma, infections or tumour excision: a comprehensive review of the literature. Eur J Med Res. (2021) 26:118. doi:  10.1186/s40001-021-00593-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Zekry KM, Yamamoto N, Hayashi K, Takeuchi A, Alkhooly AZA, Abd-Elfattah AS, et al. Reconstruction of intercalary bone defect after resection of Malignant bone tumor. J Orthop Surg (Hong Kong). (2019) 27:2309499019832970. doi:  10.1177/2309499019832970 [DOI] [PubMed] [Google Scholar]
  • 5. Fuchs B, Ossendorf C, Leerapun T, Sim FH. Intercalary segmental reconstruction after bone tumor resection. Eur J Surg Oncol. (2008) 34:1271–6. doi:  10.1016/j.ejso.2007.11.010 [DOI] [PubMed] [Google Scholar]
  • 6. Xu M, Xu M, Zhang S, Li H, Qiuchi AI, Yu X, et al. Comparative efficacy of intraoperative extracorporeal irradiated and alcohol-inactivated autograft reimplantation for the management of osteosarcomas-a multicentre retrospective study. World J Surg Oncol. (2021) 19:157. doi:  10.1186/s12957-021-02271-w [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Wu PK, Chen CF, Chen CM, Cheng YC, Tsai SW, Chen TH, et al. Intraoperative extracorporeal irradiation and frozen treatment on tumor-bearing autografts show equivalent outcomes for biologic reconstruction. Clin Orthop Relat Res. (2018) 476:877–89. doi:  10.1007/s11999.0000000000000022 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Lee SY, Jeon DG, Cho WH, Song WS, Kim BS. Are pasteurized autografts durable for reconstructions after bone tumor resections? Clin Orthop Relat Res. (2018) 476:1728–37. doi:  10.1007/s11999.0000000000000100 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Zekry KM, Yamamoto N, Hayashi K, Takeuchi A, Higuchi T, Abe K, et al. Intercalary frozen autograft for reconstruction of Malignant bone and soft tissue tumours. Int Orthop. (2017) 41:1481–7. doi:  10.1007/s00264-017-3446-x [DOI] [PubMed] [Google Scholar]
  • 10. Yamamoto N, Hayashi K, Tsuchiya H. Progress in biological reconstruction and enhanced bone revitalization for bone defects. J Orthop Sci. (2019) 24:387–92. doi:  10.1016/j.jos.2019.01.015 [DOI] [PubMed] [Google Scholar]
  • 11. Igarashi K, Yamamoto N, Shirai T, Hayashi K, Nishida H, Kimura H, et al. The long-term outcome following the use of frozen autograft treated with liquid nitrogen in the management of bone and soft-tissue sarcomas. Bone Joint J. (2014) 96-b:555–61. doi: 10.1302/0301-620X.96B4.32629 [DOI] [PubMed] [Google Scholar]
  • 12. Poffyn B, Sys G, Van Maele G, Van Hoorebeke L, Forsyth R, Verstraete K, et al. Radiographic analysis of extracorporeally irradiated autografts. Skeletal Radiol. (2010) 39:999–1008. doi:  10.1007/s00256-010-0889-1 [DOI] [PubMed] [Google Scholar]
  • 13. Enneking WF, Dunham W, Gebhardt MC, Malawar M, Pritchard DJ. A system for the functional evaluation of reconstructive procedures after surgical treatment of tumors of the musculoskeletal system. Clin orthop relatr. (1993) null:241–6. doi: 10.1097/00003086-199301000-00035 [DOI] [PubMed] [Google Scholar]
  • 14. Yang J, Zhu B, Fu K, Yang Q. The long-term outcomes following the use of inactivated autograft in the treatment of primary Malignant musculoskeletal tumor. J Orthop Surg Res. (2015) 10:177. doi:  10.1186/s13018-015-0324-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. Yang J, Li W, Feng R, Li D. Intercalary frozen autografts for reconstruction of bone defects following meta-/diaphyseal tumor resection at the extremities. BMC Musculoskelet Disord. (2022) 23:890. doi:  10.1186/s12891-022-05840-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Hindiskere S, Doddarangappa S, Chinder PS. What are the challenges and complications of sterilizing autografts with liquid nitrogen for Malignant bone tumors? A preliminary report. Clin Orthop Relat Res. (2020) 478:2505–19. doi:  10.1097/CORR.0000000000001347 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Tsuchiya H, Wan SL, Sakayama K, Yamamoto N, Nishida H, Tomita K. Reconstruction using an autograft containing tumour treated by liquid nitrogen. J Bone Joint Surg Br. (2005) 87:218–25. doi:  10.1302/0301-620x.87b2.15325 [DOI] [PubMed] [Google Scholar]
  • 18. Parmegiani L, Accorsi A, Cognigni GE, Bernardi S, Troilo E, Filicori M. Sterilization of liquid nitrogen with ultraviolet irradiation for safe vitrification of human oocytes or embryos. Fertil steril. (2010) 94:1525–8. doi:  10.1016/j.fertnstert.2009.05.089 [DOI] [PubMed] [Google Scholar]
  • 19. Wisanuyotin T, Paholpak P, Sirichativapee W, Kosuwon W. Risk factors and outcomes for failure of biological reconstruction after resection of primary Malignant bone tumors in the extremities. Sci Rep. (2021) 11:20444. doi:  10.1038/s41598-021-00092-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20. Yasin NF, Ajit Singh V, Saad M, Omar E. Which is the best method of sterilization for recycled bone autograft in limb salvage surgery: a radiological, biomechanical and histopathological study in rabbit. BMC Cancer. (2015) 15:289. doi: 10.1186/s12885-015-1234-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. Li Y, Yang Y, Huang Z, Shan H, Xu H, Niu X. Bone defect reconstruction with autologous bone inactivated with liquid nitrogen after resection of primary limb Malignant tumors: An observational study. Med (Baltimore). (2020) 99:e20442. doi:  10.1097/MD.0000000000020442 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. Ozger H, Alpan B, Eralp L, Valiyev N, Sungur M, Aycan OE, et al. Is liquid nitrogen recycled bone and vascular fibula combination the biological reconstruction of choice in lower extremity long bone tumor-related defects? J Surg Oncol. (2023) 128:902–15. doi:  10.1002/jso.27385 [DOI] [PubMed] [Google Scholar]
  • 23. Ebeid WA, Hassan MHA. Functional outcome following proximal tibial osteosarcoma resection and reconstruction by modular endoprosthesis. Ann Surg Oncol. (2023) 30:1914–25. doi:  10.1245/s10434-022-12788-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. Zan P, Wang H, Cai Z, Shen J, Sun W. Revision surgeries for tumor endoprostheses around the knee joint: a mid-long-term follow-up of 20 cases. World J Surg Oncol. (2022) 20:76. doi:  10.1186/s12957-022-02542-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Pereira CM, Pinto FFE, Nakagawa SA, Chung WT. Reconstruction with unconventional endoprostheses after resection of primary distal femoral bone tumors: implant survival and functional outcomes. Rev Bras Ortop (Sao Paulo). (2022) 57:1030–8. doi:  10.1055/s-0042-1748966 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. Hayashi K, Yamamoto N, Takeuchi A, Miwa S, Igarashi K, Higuchi T, et al. Clinical course of grafted cartilage in osteoarticular frozen autografts for reconstruction after resection of Malignant bone and soft-tissue tumor involving an epiphysis. J Bone Oncol. (2020) 24:100310. doi:  10.1016/j.jbo.2020.100310 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. Subhadrabandhu S, Takeuchi A, Yamamoto N, Shirai T, Nishida H, Hayashi K, et al. Frozen autograft-prosthesis composite reconstruction in Malignant bone tumors. Orthopedics. (2015) 38:e911–8. doi:  10.3928/01477447-20151002-59 [DOI] [PubMed] [Google Scholar]
  • 28. Xu G, Miwa S, Yamamoto N, Hayashi K, Takeuchi A, Igarashi K, et al. Pedicle frozen autograft-prosthesis composite reconstructions for Malignant bone tumors of the proximal femur. BMC Musculoskelet Disord. (2020) 21:81. doi:  10.1186/s12891-020-3112-0 [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.


Articles from Frontiers in Oncology are provided here courtesy of Frontiers Media SA

RESOURCES